GlassScriptPhysician profile
Ghulam Khaleeq
NPI 1255545224
$9,901.39
in general payments reported to CMS, 2019-2025
41 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $856 · 2021: $1,215 · 2022: $1,814 · 2023: $1,682 · 2024: $1,582 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,748 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.66 |
| Education | $513.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,015.63 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,373.11 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $1,232.34 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Glaxosmithkline, LLC. | $941.60 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $778.70 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $533.40 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $449.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $408.39 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $349.95 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $171.49 | 2022-2024 | |
| United Therapeutics Corporation | $146.27 | 2020-2024 | Tyvaso |
| Viatris Specialty LLC | $144.02 | 2025 | Yupelri |
| Insmed, INC. | $128.68 | 2019-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $104.47 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $103.08 | 2019-2025 | Xolair |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Khaleeq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.